Assignee
CELGENE CAR LLC
BM·43 granted patents·5 pending applications·226 citations·filing 2014–2021
Top patents by PatentIndex Score
48 records- 0197US9987276B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE CAR LLC·Filed 2016·Granted Jun 5, 2018·23 cites·26 claims
- 0296US10577380B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2019·Granted Mar 3, 2020·10 cites·4 claims
- 0395US10010548B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2016·Granted Jul 3, 2018·15 cites·4 claims
- 0494US10253040B1MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2017·Granted Apr 9, 2019·12 cites·15 claims
- 0594US9867824B2Heterocyclic compounds and uses thereofCELGENE CAR LLC·Filed 2016·Granted Jan 16, 2018·11 cites·14 claims
- 0693US10894796B2MK2 inhibitors, synthesis thereof, and intermediates theretoCELGENE CAR LLC·Filed 2018·Granted Jan 19, 2021·8 cites·19 claims
- 0793US9980964B2ERK inhibitors and uses thereofCELGENE CAR LLC·Filed 2017·Granted May 29, 2018·11 cites·28 claims
- 0893US9868723B2Mutant-selective EGFR inhibitors and uses thereofCELGENE CAR LLC·Filed 2016·Granted Jan 16, 2018·10 cites·16 claims
- 0993US9790235B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2016·Granted Oct 17, 2017·12 cites·18 claims
- 1093US9765038B2Heteroaryl compounds and uses thereofCELGENE CAR LLC·Filed 2016·Granted Sep 19, 2017·11 cites·20 claims
- 1192US10882867B2Forms and compositions of a MK2 inhibitorCELGENE CAR LLC·Filed 2018·Granted Jan 5, 2021·8 cites·23 claims
- 1292US10081606B2Heteroaryl compounds and uses thereofCELGENE CAR LLC·Filed 2017·Granted Sep 25, 2018·8 cites·8 claims
- 1391US11098057B29,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereofCELGENE CAR LLC·Filed 2018·Granted Aug 24, 2021·5 cites·15 claims
- 1491US9796700B2ERK inhibitors and uses thereofCELGENE CAR LLC·Filed 2016·Granted Oct 24, 2017·7 cites·17 claims
- 1590US11351168B12,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2020·Granted Jun 7, 2022·2 cites·3 claims
- 1690US11230551B2Deuterated analogs of MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2018·Granted Jan 25, 2022·5 cites·13 claims
- 1790US10828300B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE CAR LLC·Filed 2018·Granted Nov 10, 2020·3 cites·27 claims
- 1890US10596172B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2018·Granted Mar 24, 2020·5 cites·3 claims
- 1989US11096942B2Heterocyclic compounds and uses thereofCELGENE CAR LLC·Filed 2019·Granted Aug 24, 2021·2 cites·14 claims
- 2089US10138256B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2014·Granted Nov 27, 2018·11 cites·12 claims
- 2188US10434101B2Heterocyclic compounds and uses thereofCELGENE CAR LLC·Filed 2018·Granted Oct 8, 2019·4 cites·17 claims
- 2288US9663524B2Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitorsCELGENE CAR LLC·Filed 2014·Granted May 30, 2017·15 cites·27 claims
- 2387US9695132B2Heteroaryl compounds and uses thereofCELGENE CAR LLC·Filed 2016·Granted Jul 4, 2017·5 cites·63 claims
- 2486US11124525B2Heteroaryl compounds useful as MK2 inhibitorsCELGENE CAR LLC·Filed 2018·Granted Sep 21, 2021·5 cites·17 claims
- 2585US11655257B2MK2 inhibitors, synthesis thereof, and intermediates theretoCELGENE CAR LLC·Filed 2021·Granted May 23, 2023·1 cites·10 claims
- 2685US10005738B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2017·Granted Jun 26, 2018·3 cites·20 claims
- 2785US10004741B2Solid forms of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2017·Granted Jun 26, 2018·3 cites·20 claims
- 2884US11584757B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2020·Granted Feb 21, 2023·1 cites·20 claims
- 2983US11629153B2Forms and compositions of a MK2 inhibitorCELGENE CAR LLC·Filed 2020·Granted Apr 18, 2023·1 cites·33 claims
- 3082US10570099B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2018·Granted Feb 25, 2020·2 cites·22 claims
- 3181US10946016B2Solid forms of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2018·Granted Mar 16, 2021·1 cites·17 claims
- 3280US10189794B2Heteroaryl compounds and uses thereofCELGENE CAR LLC·Filed 2017·Granted Jan 29, 2019·2 cites·56 claims
- 3377US10065966B2Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinasesCELGENE CAR LLC·Filed 2017·Granted Sep 4, 2018·2 cites·27 claims
- 3477US2022218704A1Heterocyclic compounds and uses thereofCELGENE CAR LLC·Filed 2021·Application pending·0 cites
- 3574US11292772B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2020·Granted Apr 5, 2022·0 cites·14 claims
- 3673US2022062280A1Solid forms of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2021·Application pending·0 cites
- 3772US11760763B2Heteroaryl compounds useful as MK2 inhibitorsCELGENE CAR LLC·Filed 2021·Granted Sep 19, 2023·0 cites·11 claims
- 3871US10774052B2Heteroaryl compounds and uses thereofCELGENE CAR LLC·Filed 2019·Granted Sep 15, 2020·0 cites·31 claims
- 3971US2022332687A1Heteroaryl compounds and uses thereofCELGENE CAR LLC·Filed 2020·Application pending·0 cites
- 4070US10005760B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2015·Granted Jun 26, 2018·1 cites·21 claims
- 4169US11542492B2Ligand-directed covalent modification of proteinCELGENE CAR LLC·Filed 2017·Granted Jan 3, 2023·1 cites·7 claims
- 4262US10618902B2Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinasesCELGENE CAR LLC·Filed 2018·Granted Apr 14, 2020·0 cites·15 claims
- 4360US11098061B2MK2 inhibitors and uses thereofCELGENE CAR LLC·Filed 2018·Granted Aug 24, 2021·0 cites·14 claims
- 4459US10202364B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2018·Granted Feb 12, 2019·0 cites·16 claims
- 4555US9694086B2HCV protease inhibitors and uses thereofCELGENE CAR LLC·Filed 2015·Granted Jul 4, 2017·0 cites·18 claims
- 4655US9676785B2HCV protease inhibitors and uses thereofCELGENE CAR LLC·Filed 2014·Granted Jun 13, 2017·0 cites·32 claims
- 4753US2022251105A1Methods of treating a mk2-mediated disorderCELGENE CAR LLC·Filed 2020·Application pending·0 cites
- 4848US2017216432A1Methods of treating a disease or disorder associated with bruton's tyrosine kinaseCELGENE CAR LLC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CELGENE CAR LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →